LEADER 01008nam a2200289 i 4500
001 991001959439707536
005 20020507154503.0
008 000229s1992    it            ||| | fre  
020   $a8823801265
035   $ab11588986-39ule_inst
035   $aLE02728096$9ExL
040   $aDip.to Studi Giuridici$bita
082 0 $a340
084   $aC-XXIII/A
100 1 $aSchena, Leo$0132178
245 13$aLe français juridique /$cLeo Schena, Benito Proietto
260   $aMilano :$bEGEA,$cc1992
300   $axiv, 508 p. ;$c23 cm.
490 0 $aLezioni e letture di lingue
650  4$aDiritto$xLinguaggio
700 1 $aProietto, Benito$eauthor$4http://id.loc.gov/vocabulary/relators/aut$0252517
907   $a.b11588986$b01-03-17$c02-07-02
912   $a991001959439707536
945   $aLE027 C-XXIII/A 1$g1$i2027000251094$lle027$o-$pE0.00$q-$rl$s-  $t0$u0$v0$w0$x0$y.i11798300$z02-07-02
996   $aFrancais juridique$9443572
997   $aUNISALENTO
998   $ale027$b01-01-00$cm$da  $e-$ffre$git $h3$i1

LEADER 03451nam  2200577Ia 450 
001 9910777453103321
005 20230607221756.0
010   $a1-280-24804-1
035   $a(CKB)1000000000450557
035   $a(EBL)3377603
035   $a(SSID)ssj0000119076
035   $a(PQKBManifestationID)11145624
035   $a(PQKBTitleCode)TC0000119076
035   $a(PQKBWorkID)10057857
035   $a(PQKB)11612462
035   $a(OCoLC)229431501
035   $a(MiAaPQ)EBC3377603
035   $a(EXLCZ)991000000000450557
100   $a20020131d2001      uy             0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 00$aCDC anthrax vaccine safety & efficacy research program $einterim report$b[electronic resource] /$fInstitute of Medicine
210   $aWashington, D.C. $cNational Academy Press$dc2001
215   $a1 online resource (57 p.)
300   $a"Prepublication copy; uncorrected proofs".
311   $a9786610248049 
311   $a0-309-57987-2 
320   $aIncludes bibliographical references.
327   $a""CDC Anthrax Vaccine Safety & Efficacy Research Program""; ""Copyright""; ""Contents""; ""Preface""; ""Acknowledgments""; ""REVIEWERS""; ""Executive Summary""; ""PROJECT-SPECIFIC FINDINGS AND RECOMMENDATIONS""; ""NCID-Directed Projects in the Research Program""; ""Human Clinical Trial, or Part A""; ""Animal dose ranging and challenge studies, or Part B""; ""Assays addressing correlates of immunity, or Part C""; ""Human Leukocyte Antigen (HLA) substudy""; ""NIP-Directed Projects of the Research Program""
327   $a""Survey of knowledge, attitudes, and beliefs of military personnel about the anthrax vaccine""""Survey of knowledge, attitudes, and beliefs of military vaccinee providers about VAERS reporting""; ""CDC proposal for use of the Short Form 36""; ""Remaining components of the research program directed by the NIP""; ""1 Introduction and Background ""; ""ANTHRAX DISEASE AND PREVENTION""; ""Anthrax Disease""; ""Anthrax Vaccine""; ""VACCINE RELATED ADVERSE EVENTS""; ""POLICY CONTEXT OF REPORT""; ""Anthrax Vaccination Policy""; ""CDC'S RESPONSE TO CONGRESS""
327   $a""2 Interim Findings and Recommendations """"NCID RESEARCH ACTIVITIES""; ""Part A: Clinical Trial""; ""CDC proposal for use of the Short Form 36""; ""Part B: Non-human Primate Dose-Ranging and Challenge Study""; ""Part C: Assays of Immunologic Correlates of Protection""; ""NIP RESEARCH ACTIVITIES""; ""Knowledge, Attitudes, and Beliefs of Military Personnel about the Anthrax Vaccine""; ""Knowledge, Attitudes, and Beliefs of Vaccine Providers about VAERS Reporting""; ""Data Mining Using the VAERS Database""; ""Meta-Analysis of Existing Studies on the Anthrax Vaccine""; ""REFERENCES""
327   $a""ACRONYMS""""Appendix A Study Activities ""; ""Appendix B Biographical Sketches ""
606   $aAnthrax$xVaccination
606   $aVaccines$xEffectiveness
606   $aVaccines$xSafety measures
615  0$aAnthrax$xVaccination.
615  0$aVaccines$xEffectiveness.
615  0$aVaccines$xSafety measures.
676   $a616.956
712 02$aInstitute of Medicine (U.S.)
712 02$aCommunicable Disease Center (U.S.)
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910777453103321
996   $aCDC anthrax vaccine safety & efficacy research program$93803389
997   $aUNINA